immunostimulant

Bropirimine (U-54461) (U-54461) is a biological response modifier that is thought to act through the induction of lymphokines.

IPN60090 is a novel, potent, orally bioavailable, renal-type glutaminase (GLS1)-specific inhibitor with an IC50 value of 31 nM for GLS1. IPN60090 has potential anticancer and immunostimulant/immunomodulatory activity, selectively targets, binds, and inhibits human glutaminase, and can be used to study GLS1-mediated diseases.

Quadrol (EDTP) is an immunostimulant, accelerated wound healing.

N-Methylsarcosine (Dimethylglycine) is used as an athletic performance enhancer and immunostimulant. It is also used in the treatment of autism, epilepsy and mitochondrial disease. It is also employed as a biomarker of protein degradation in chronic obstructive lung disease (COPD) patients. Further, it is used as a substrate to identify, differentiate and characterize amino acid methyltransferase. It plays an important role in the development of glycine-based ionic liquids and emulsifiers.

L-Allothreonine (L-allo-Threonine) is an essential amino acid in humans. L-Allothreonine is abundant in human plasma, particularly in newborns. Severe deficiency of threonine causes neurological dysfunction and lameness in experimental animals. L-Allothreonine is an immunostimulant which promotes the growth of thymus gland. L-Allothreonine also can probably promote cell immune defense function. L-Allothreonine is highly concentrated in meat products, cottage cheese, and wheat germ.

Loxoribine (RWJ 21757) is a guanosine analog. Loxoribine is an orally bioavailable and selective Toll-like receptor (TLR) 7 agonist. It has anti-viral and anti-tumor activities.Loxoribine is a potent new immunostimulant with a relatively broad spectrum of immunobiological activities.

TLR7 agonist27 (compound 24) is an effective TLR7 agonist with an EC50 of 238.1 nM. It exhibits weak agonistic activity towards NOD2 (nucleotide-binding oligomerization domain 2) with an EC50 of 6.2 μM. TLR7 agonist27 serves as a potent immunostimulant and can be utilized as a vaccine adjuvant and or an immunotherapeutic agent.

LH 1 is an immunostimulant used in antitumor treatment.

Roquinimex (FCF89) (Linomide) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity; inhibits angiogenesis and reduces the secretion of TNF alpha.

ODN 1826 is a 20-mer DNA strand, a TLR9 agonist and an immunostimulant, with anti-tumor and cardioprotective effects, promoting apoptosis, and stimulating the production of NO and iNOS. ODN 1826 is a CpG DNA mimetic that can be used as an adjuvant for synthetic vaccines.

Sovipostobart, an immunoglobulin G1-kappa monoclonal antibody targeting CTLA-4 in Homo sapiens, features a cleavable prodomain. This compound serves as both an immunostimulant and antineoplastic [1].

Rolistobart is a humanized IgG4-κ monoclonal antibody targeting LILRB4/CD85k. It functions as an immunostimulant and antineoplastic agent [1].

Perenostobart is a humanized IgG4-κ monoclonal antibody designed to target the ectonucleoside triphosphate diphosphohydrolase-1 (ENTPD1/CD39) protein, an enzyme expressed on immunosuppressive cells within the tumor microenvironment, thereby conferring the antibody with dual immunostimulatory and direct antineoplastic properties for oncology applications.

Muzastotug is a humanized IgG1-kappa monoclonal antibody targeting CTLA4, functioning as an immunostimulant and antineoplastic [1].

Lipustobart is an IgG4-kappa humanized monoclonal antibody targeting PDCD1 (programmed cell death 1, PD1, PD-1, CD279), with immunostimulant and antineoplastic activity [1].

Enlonstobart is a humanized IgG4-κ monoclonal antibody targeting PDCD1, functioning as both an immunostimulant and antineoplastic agent [1].

Danburstotug (IMC-001), an immunostimulant and antineoplastic [1], is a humanized IgG1-lambda monoclonal antibody targeting CD274 (PDL1, B7 homologue 1, B7H1).

Abazistobart is an immunostimulant and antitumor agent targeting programmed cell death protein 1 (PDCD1). This chimeric humanized monoclonal antibody specifically binds to PDCD1, blocking associated signaling pathways, thereby activating the immune system to exert antitumor effects. Abazistobart holds promise for cancer research applications.